Patents Assigned to Genetics Institute
  • Bone and cartilage inductive proteins
    Patent number: 7378392
    Abstract: Purified cartilage and/or bone inductive proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and/or cartilage defects and in wound healing and related tissue repair.
    Type: Grant
    Filed: October 6, 1994
    Date of Patent: May 27, 2008
    Assignee: Genetics Institute, LLC
    Inventors: Rodney M. Hewick, Jack H. Wang, John M. Wozney, Anthony J. Celeste
  • PD-L2 Molecules: Novel PD-1 Ligands and Uses Therefor
    Publication number: 20080118511
    Abstract: The invention provides isolated nucleic acids molecules, designated PD-L2 nucleic acid molecules, which encode novel B7-related molecules which are ligands for PD-1. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PD-L2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PD-L2 gene has been introduced or disrupted. The invention further provides isolated PD-L2 polypeptides, fusion proteins, antigenic peptides and anti-PD-L2 antibodies. The invention still further provides methods for promoting or inhibiting the interaction between PD-L2 and PD-1. Diagnostic and treatment methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: June 20, 2007
    Publication date: May 22, 2008
    Applicants: Dana-Farber Cancer Institute, Inc., Genetics Institute LLC
    Inventors: Gordon Freeman, Irene Chernova, Tatyana Chernova, Nelly Malenkovich, Clive R. Wood
  • Schizophrenia associated genes, proteins and biallelic markers
    Patent number: 7371811
    Abstract: The invention concerns the human sbg1, g34665, sbg2, g35017 and g35018 genes, polynucleotides, polypeptides biallelic markers, and human chromosome 13q31-q33 biallelic markers. The invention also concerns the association established between schizophrenia and bipolar disorder and the biallelic markers and the sbg1, g34665, sbg2, g35017 and g35018 genes and nucleotide sequences. The invention provides means to identify compounds useful in the treatment of schizophrenia, bipolar disorder and related diseases, means to determine the predisposition of individuals to said disease as well as means for the disease diagnosis and prognosis.
    Type: Grant
    Filed: June 6, 2005
    Date of Patent: May 13, 2008
    Assignee: Serono Genetics Institute S.A.
    Inventors: Daniel Cohen, Marta Blumenfeld, Ilya Chumakov, Lydie Bougueleret, Bernard Bihain, Laurent Essioux
  • Tendon-inducing methods
    Patent number: 7365052
    Abstract: Compositions of proteins with tendon/ligament-like tissue inducing activity are disclosed. The compositions are useful in the treatment of tendinitis and tendon or ligament defects and in related tissue repair.
    Type: Grant
    Filed: June 17, 2005
    Date of Patent: April 29, 2008
    Assignees: Genetics Institute, LLC., President and Fellows of Harvard College
    Inventors: Anthony J. Celeste, John M. Wozney, Vicki A. Rosen, Neil M. Wolfman, Gerald H. Thomsen, Douglas A. Melton
  • Megakaryocyte stimulating factors
    Patent number: 7361738
    Abstract: Novel polypeptides of human megakaryocyte stimulating factors (MSFs). Pharmaceutical compositions containing same, and methods for their preparation and use are provided.
    Type: Grant
    Filed: June 28, 2005
    Date of Patent: April 22, 2008
    Assignee: Genetics Institute, Inc.
    Inventors: Katherine Turner, Steven C. Clark, Kenneth Jacobs, Rodney M. Hewick, Thomas G. Gesner
  • Variants and exons of the GlyT1 transporter
    Patent number: 7358066
    Abstract: The present invention provides polypeptide and polynucleotide sequences for novel splice variants of the sodium and chloride-dependent glycine transporter type 1 (GlyT1). These polypeptides and polynucleotides are useful in the treatment and diagnosis of disorders such as neurological and psychiatric disorders including schizophrenia. The invention also provides antibodies directed specifically against these novel polypeptides, and kits comprising the herein-described polynucleotides, polypeptides, and/or antibodies.
    Type: Grant
    Filed: July 22, 2002
    Date of Patent: April 15, 2008
    Assignee: Serono Genetics Institute S.A.
    Inventors: Gilbert Thill, Philippe Jais, Pascale Grel, Sandrine Mace
  • Metabolic gene polynucleotides and polypeptides and uses thereof
    Patent number: 7348406
    Abstract: The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. GMG-3, GMG-4, Cluster 1, GMG-6A, or GMG-6B polypeptides have been identified that are beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing body mass and for treating metabolic-related diseases and disorders. These metabolic-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.
    Type: Grant
    Filed: January 15, 2002
    Date of Patent: March 25, 2008
    Assignee: Serono Genetics Institute S.A.
    Inventors: Mary Ruth Erickson, Barbara A. Chicca, Bernard Bihain, Hiroaki Tanaka
  • Agonists and antagonists of prolixin for the treatment of metabolic disorders
    Patent number: 7344843
    Abstract: The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to, hyperlipidemia, atherosclerosis, insulin resistance, diabetes, and hypertension. In particular, the invention provides for methods of identifying and using AGONISTS and ANTAGONISTS of PROLIXIN activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity.
    Type: Grant
    Filed: October 14, 2002
    Date of Patent: March 18, 2008
    Assignee: Serono Genetics Institute S.A.
    Inventors: John Lucas, Deno Dialynas, Kristen Briggs
  • Nucleic acids encoding OBG3 globular head and uses thereof
    Patent number: 7338787
    Abstract: The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, globular OBG3, has been identified that reduces weight gain in animals. This compound should be effective for reducing body mass and for treating obesity-related diseases and disorders. These obesity-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.
    Type: Grant
    Filed: October 20, 2004
    Date of Patent: March 4, 2008
    Assignee: Serono Genetics Institute S.A.
    Inventors: Joachim Fruebis, Mary Ruth Erickson, Frances Yen-Potin, Bernard Bihain
  • Humanized immunoglobulin reactive with B7 molecules and methods of treatment therewith
    Publication number: 20080050368
    Abstract: The invention relates to humanized anti-B7-2 and anti-B7-1 antibodies, wherein each comprise a variable region of non-human origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.
    Type: Application
    Filed: September 26, 2006
    Publication date: February 28, 2008
    Applicant: Genetics Institute, LLC
    Inventors: Abbie Cheryl Celniker, Gary S. Gray
  • GMG-3 GMG-4 and GMG-6 polynucleotides and polypeptides and uses thereof
    Patent number: 7326678
    Abstract: The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. GMG-3, GMG-4, Cluster 1, GMG-6A, or GMG-6B polypeptides have been identified that are beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing body mass and for treating metabolic-related diseases and disorders. These metabolic-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.
    Type: Grant
    Filed: January 15, 2002
    Date of Patent: February 5, 2008
    Assignee: Serono Genetics Institute S.A.
    Inventors: Mary Ruth Erickson, Barbara A. Chicca, Bernard Bihain, Hiroaki Tanaka, Tom Chu, Deno P. Dialynas, Aaron Scalia
  • HUMAN cDNAs AND PROTEINS AND USES THEREOF
    Publication number: 20080026427
    Abstract: The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.
    Type: Application
    Filed: September 26, 2007
    Publication date: January 31, 2008
    Applicant: Serono Genetics Institute S.A.
    Inventors: STEPHANE BEJANIN, Hiroaki Tanaka
  • Methods and compositions for healing and repair of articular cartilage
    Patent number: 7323445
    Abstract: Methods and compositions are provided for the treatment of articular cartilage defects and disease involving the combination of tissue, such as osteochondral grafts, with active growth factor. The active growth factor is preferably a composition containing at least one bone morphogenetic protein and a suitable carrier. The method results in the regeneration and/or functional repair of articular cartilage tissue.
    Type: Grant
    Filed: February 18, 2004
    Date of Patent: January 29, 2008
    Assignee: Genetics Institute, LLC
    Inventors: Renwen Zhang, Diane Peluso, Elisabeth Morris
  • Human Gil-19/AE289 polynucleotides
    Patent number: 7307161
    Abstract: Novel human GIL-19/AE289 protein is disclosed which shows a high degree of homology to interleukin-10 (IL-10). Polynucleotides encoding such protein are also enclosed.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: December 11, 2007
    Assignee: Genetics Institute, LLC
    Inventors: Kenneth Jacobs, Lynette Fouser, Vikki Spaulding, Dejun Xuan
  • BMP products
    Patent number: 7300772
    Abstract: Purified BMP-2 and BMP-4 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair.
    Type: Grant
    Filed: March 9, 2001
    Date of Patent: November 27, 2007
    Assignee: Genetics Institute, LLC
    Inventors: Elizabeth A. Wang, John M. Wozney, Vicki A. Rosen
  • ?-Secretase variant
    Patent number: 7291495
    Abstract: The invention provides polynucleotides and polypeptides encoding an isolated amyloid inhibitor protein (APIP) and compositions thereof. The polypeptides of the subject invention can be used to inhibit the catabolism or sequential cleavage of amyloid beta precursor protein (APP) by sequential cleavage of APP by beta secretase and gamma secretase.
    Type: Grant
    Filed: May 3, 2004
    Date of Patent: November 6, 2007
    Assignee: Serono Genetics Institute S.A.
    Inventors: Stephane Bejanin, Hiroaki Tanaka
  • LSR receptor, its activity, its cloning, and its applications to the diagnosis, prevention and/or treatment of obesity and related risks or complications
    Patent number: 7291709
    Abstract: The present invention relates to a new complex receptor polypeptide LSR (Lipolysis Stimulated Receptor), characterized by its functional activities, the cloning of the cDNAs complementary to the messenger RNAs encoding each of the subunits of the multimeric complex, vectors and transformed cells, methods of diagnosis and of selection of compounds which can be used as medicament for the prevention and/or treatment of pathologies and/or of pathogeneses such as obesity and anorexia, hyperlipidemias, atherosclerosis, diabetes, hypertension, and more generally the various pathologies associated with abnormalities in the metabolism of cytokines.
    Type: Grant
    Filed: August 27, 2003
    Date of Patent: November 6, 2007
    Assignees: Serono Genetics Institute S.A., Institut National de la Sante de la Recherche Medicale (INSERM)
    Inventors: Bernard Bihain, Lydie Bougueleret, Frances Yen-Potin
  • Human cDNAs and proteins and uses thereof
    Patent number: 7285631
    Abstract: The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.
    Type: Grant
    Filed: October 15, 2001
    Date of Patent: October 23, 2007
    Assignee: Serono Genetics Institute S.A.
    Inventors: Stephane Bejanin, Hiroaki Tanaka
  • Antibodies that bind to interleukin-22
    Patent number: 7279559
    Abstract: Inhibitors of IL-22 are disclosed as well as pharmaceutical compositions and methods of using same. The inhibitors include IL-22 antibodies and are useful for treating inflammatory disorders.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: October 9, 2007
    Assignee: Genetics Institute, LLC
    Inventors: Kenneth Jacobs, Debra D. Pittman, Lynette Fouser, Vikki Spaulding, Dejun Xuan
  • Xobesin agonists and antagonists for the treatment of metabolic disorders
    Patent number: 7276342
    Abstract: The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to, hyperlipidemia, atherosclerosis, insulin resistance, diabetes, and hypertension. In particular, the invention provides for methods of identifying and using AGONISTS and ANTAGONISTS of XOBESIN activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity.
    Type: Grant
    Filed: July 31, 2002
    Date of Patent: October 2, 2007
    Assignee: Serono Genetics Institute S.A.
    Inventors: John Lucas, Deno P. Dialynas, Kristen Briggs